The approval by Health Canada for use of the post-partum depression medication Zuranalone in 2026 for Canadian mothers is welcome news.

The medication has been used in the U.S., U.K. and European Union to great affect.

Kristin Reynolds, an Associate Professor with the Department of Psychology at the University of Manitoba, shares the difference between the more common “baby blues” and post-partum depression.

“A really important distinction between a clinical peripartum/perinatal depression and baby blues is that symptoms are longer lasting. People might have a depressed mood, appetite change, change in sleep, change in energy, change in feelings of excessive guilt.”

Reynolds added that if a woman’s family members have struggled with post-partum depression, it is possible they will as well due to a strong genetic component.

Learn more about what post-partum depression is, the symptoms, and the resources available for mothers outside of medications.

Catch Thompson Today this afternoon at 12:40 and 5:10.